Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: A novel mechanism of retinoid growth - Inhibitory activity

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3360-3368

  Appierto, Valentina ^a   Tiberio, Paola ^a   Cavadini, Elena ^a   Casalini, Patrizia ^a   Cappelletti, Graziella ^b   Formelli, Franca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO N (4 HYDROXYPHENYL)RETINAMIDE 4 OXO 4 FENRETINIDE; ANTIMITOTIC AGENT; BUB1 RELATED PROTEIN; CYCLIN B1; KINESIN; RETINOID; TANKYRASE; TUBULIN; UNCLASSIFIED DRUG;

ANAPHASE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CENTROSOME; CONTROLLED STUDY; DEPOLYMERIZATION; HUMAN; HUMAN CELL; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INDEX; MITOSIS INHIBITION; MITOSIS SPINDLE; MOLECULAR INTERACTION; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPINDLE POLE BODY;

ACTINS; ANTIMITOTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; FENRETINIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; KINESIN; MICROFILAMENT PROTEINS; MICROSCOPY, FLUORESCENCE; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; MITOTIC INDEX; MITOTIC SPINDLE APPARATUS; OVARIAN NEOPLASMS; POLYMERS; RETINOIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANKYRASES; TUBULIN;

EID: 73149092085     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0798     Document Type: Article

References (42)

1. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 1998;5:11-9.
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
3. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
4. Chiesa F, Tradati N, Grigolato R, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 2005;115:625-9.
5. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-9.
6. De Palo G, Mariani L, Camerini T, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002;86:24-7.
7. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
8. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;17:1065-71.
9. Villani MG, Appierto V, Cavadini E, et al. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 2004;10:6265-75.
10. Villani MG, Appierto V, Cavadini E, et al. 4-Oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2/M cell cycle arrest and apoptosis in fenretinide-sensitive and -resistant cell lines. Cancer Res 2006;66:3238-47.
11. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci 1983;80:2926-30.
12. Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, Formelli F. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 2004;1:270-9.
13. Cappelletti G, Tedeschi G, Maggioni MG, Negri A, Nonnis S, Maci R. The nitration of tau protein in neurone-like PC12 cells. FEBS Lett 2004;562:35-9.
14. Castoldi M, Popov AV. Purification of brain tubulin through two cycles of polymerization-depolymerization in a high-molarity buffer. Protein Expr Purif 2003;32:83-8.
15. Passarella D, Giardini A, Peretto B, et al. Inhibitors of tubulin polymerization: synthesis and biological evaluation of hybrids of vindoline, anhydrovinblastine and vinorelbine with thiocolchicine, podophyllotoxin and baccatin III. Bioorg Med Chem 2008;16:6269-85.
16. Gruss OJ, Vernos I. The mechanism of spindle assembly: functions of Ran and its target TPX2. J Cell Biol 2004;66:949-55.
17. Sun QY, Schatten H. Role of NuMA in vertebrate cells: review of an intriguing multifunctional protein. Front Biosci 2006;11:1137-46.
18. Cuschieri L, Nguyen T, Vogel J. Control at the cell center: the role of spindle poles in cytoskeletal organization and cell cycle regulation. Cell Cycle 2007;6:2788-94.
19. Clarke PR, Allan LA. Cell-cycle control in the face of damage - a matter of life or death. Trends Cell Biol 2009;19:89-98.
20. Clute P, Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999;1:82-7.
21. Li W, Lan Z, Wu H, et al. BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ 1999;10:769-75.
22. Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16:3187-99.
23. Yu J, Lan J, Zhu Y, et al. The E3 ubiquitin ligase HECTD3 regulates ubiquitination and degradation of Tara. Biochem Biophys Res Commun 2008;367:805-12.
24. Chang P, Coughlin M, Mitchison TJ. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 2005;7:1133-9.
25. Clark IB, Meyer DI. Overexpression of normal and mutant Arp1α (centractin) differentially affects microtubule organization during mitosis and interphase. J Cell Sci 1999;112:3507-18.
26. Holmfeldt P, Stenmark S, Gullberg M. Differential functional interplay of TOGp/XMAP215 and the KinI kinesin MCAK during interphase and mitosis. EMBO J 2004;23:627-37.
27. Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle multipolarity is prevented by centrosomal clustering. Science 2005;307:127-9.
28. Garrett S, Auer K, Compton DA, Kapoor TM. hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division. Curr Biol 2002;12:2055-9.
29. Gaglio T, Saredi A, Compton DA. NuMA is required for the organization of microtubules into aster-like mitotic arrays. J Cell Biol 1995;131:693-708.
30. Wittmann T, Wilm M, Karsenti E, Vernos I. TPX2, A novel xenopus MAP involved in spindle pole organization. J Cell Biol 2000;149:1405-18.
31. Lingle WL, Lukasiewicz K, Salisbury JL. Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv Exp Med Biol 2005;570:393-421.
32. Gisselsson D. Mitotic instability in cancer: is there method in the madness? Cell Cycle 2005;4:1007-10.
33. Ochi T, Oda T. Structure-effect relationship in the induction of mitotic phase-specific abnormality of centrosome integrity and multipolar spindles by steroidal estrogens and their derivatives in cultured mammalian cells. J Steroid Biochem Mol Biol 2001;78:113-22.
34. Cenciarelli C, Tanzarella C, Vitale I, et al. The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis 2008;13:659-69.
35. Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Ogawa N. Rotenone induces aggregation of ã-tubulin protein and subsequent disorganization of the centrosome: relevance to formation of inclusion bodies and neurodegeneration. Neuroscience 2005;133:117-35.
36. Yih LH, Tseng YY, Wu YC, Lee TC. Induction of centrosome amplification during arsenite-induced mitotic arrest in CGL-2 cells. Cancer Res 2006;66:2098-106.
37. van Tellingen O, Sips JH, Beijnen JH, Bult A, Nooijen WJ. Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semisynthetic derivatives. Anticancer Res 1992;12:1699-715.
38. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
39. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-8.
40. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
41. Bradley G, Ling V. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994;13:223-33.
42. Burkhart CA, Kavallaris M, Band Horwitz S. The role of â-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-9.